SHINEWAY PHARMACEUTICAL GROUP LTD.

Shineway Pharmaceutical Group Ltd., founded since 1992, is a large comprehensive group with modern Chinese medicine as its dominant business. Shineway’s comprehensive competitiveness ranks among top 20 of pharmaceutical industry, taking fourth place in traditional Chinese medicine industry. As the largest traditional Chinese medicine manufacturer by market capitalization in Hong Kong stock exchange, Shineway owns “SHINEWAY” “WUFU” and “SHENMIAO” as three famous trademarks in China.
Targeting on rapidly growing pharmaceutical markets for the middle-aged, elderly, children and anti-virus, Shineway has formed three featured products, including dose forms- modern TCM injection, modern TCM soft capsules, modern TCM granules. Shineway also owns several large categories of modern TCM, with annual sales of more than 100 million RMB. Shineway Qingkailing Injection, Shineway Shenmai Injection and Shineway Shuxuening Injection are awarded “Worth Trusting Medicine of China”, which take over 70% market shares of other similar products. Shineway Huoxiangzhengqi soft capsules, Shineway Qingkailing capsules and other several products are listed as national protected TCM. Famous products including Shineway “Wufu” Xinnaoqing soft capsules and Xiao’er Qingfei Huatan granules are famous products across the country.
More than ten main varieties of“Wufu” Xinnaoqing soft capsules, Huoxiang Zhengqi soft capsules, Liyan Jiedu granules, Shujin Tongluo granules, synovitis granules and Shuxuening injections produced by the company have registered their products in nearly 20 countries, including Singapore, Vietnam, Indonesia, Thailand, Canada and Australia. The company's main trademark "SHINEWAY" has been registered in Madrid Agreement, more than 30 countries such as the United Kingdom, the United States, South Korea, Indonesia, Taiwan, Hong Kong and other regions. Products exported to overseas markets include Southeast Asia, Australia, North America and Europe. The overseas registration and sales of products have developed from zero to nearly one million US dollars (including 530,000 US dollars for self export) in 2019. 2019 is 20% higher than 2018. In the first half of 2020, the impact of the epidemic was 10% lower than that of the same period last year.
Shineway Pharmaceutical Group, as a modern Chinese medicine enterprise, has been working hard to implement the strategy of "going out" of Chinese medicine for the country. In 2014, the company began to develop a new drug SLT capsule for the treatment of Alzheimer's disease with the University of Western Sydney, Australia, which is in the process of new drug registration in Australia. Since 2015, the company and Singapore new drug company have developed and produced MLC capsules to improve brain nerves. In 2019, we will carry out cooperative research on quality standard improvement with the National Key Laboratory of traditional Chinese medicine of Macao University of science and technology.
Since 2007, the company has passed the TGA production certification in Australia for four consecutive times, and passed the production site license in Singapore and the production site license in Canada, clearing the way for the Chinese patent medicines with plant ingredients to enter the above market.